RxDoctor Payments Data

Yvette Scharf

Family · Saginaw, MINPI 1417474164

Payments from drug & device makers

$4,457in general payments, 2019–2025

Across 242 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$526
  • AbbVie$488
  • Amgen$486
  • Boehringer Ingelheim$347
  • Bayer$333
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$4,441100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,457 in reported general payments places this provider in the 90th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide106$112,468
OzempicSemaglutide40$59,736
MounjaroTirzepatide47$54,140
JardianceEmpagliflozin31$36,811
EliquisApixaban33$26,505
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$18,155
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,871
Synjardy XrEmpagliflozin/Metformin Hcl12$11,162
Tresiba Flextouch U-100Insulin Degludec12$8,040
Tresiba Flextouch U-200Insulin Degludec12$6,990
MyrbetriqMirabegron12$6,540
VascepaIcosapent Ethyl14$4,670
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,961
Atorvastatin Calcium251$2,432
Rosuvastatin Calcium104$1,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$526$166,609153 claims
Novo NordiskOzempic$1,022$59,73640 claims
Boehringer IngelheimJardiance, Synjardy Xr$347$47,97343 claims
GSKAnoro Ellipta, Trelegy Ellipta$67$33,02640 claims
PfizerEliquis$12$26,50533 claims
Astellas Pharma US IncMyrbetriq$32$6,54012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,657 family providers in Michigan.

Other family in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →